Literature DB >> 29025610

Is endoprosthesis safer than internal fixation for metastatic disease of the proximal femur? A systematic review.

Alberto Di Martino1, Nicolò Martinelli2, Mattia Loppini3, Andrea Piccioli4, Vincenzo Denaro5.   

Abstract

INTRODUCTION: Metastases to the proximal femur are usually managed surgically by tumor resection and reconstruction with an endoprosthesis, or by fixation with osteosynthesis. Still controversy remains regarding the most appropriate surgical treatment. We posed the following questions: (1) Is the frequency of surgical revision greater in patients treated with internal fixation than endoprosthetic reconstruction, and (2) Do complications that do not require surgery occur more frequently in patients treated with internal fixation rather than in those with endoprosthetic reconstruction?
MATERIALS AND METHODS: A systematic review was performed of those studies reporting on surgical revision and complication rates comparing the two surgical methods. Ten studies including 1107 patients met the inclusion criteria, three with high methodological quality, three intermediate, and four with lowquality, according to the STROBE guidelines.
RESULTS: At present, prosthetic dislocation is the most common complication observed in patients managed by prosthesis replacement of the proximal femur, while loosening was the main cause of reoperation in the fixation group. Time to reintervention ranged from 3 to 11.6 months for the prosthetic replacement and from 7.8 to 22.3 months for the fixation group. Non surgical complications, (mainly dislocations and infections) were more commonly observed in patients operated on by prosthetic replacement.
CONCLUSIONS: Implant related complications and surgery-related morbidity should be taken into account in the decision-making process for the surgical management of these patients. These data can improve the surgeon-patient communication and guide further studies on patients' survival and complications with respect to surgery.
© 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bone metastasis; Endoprosthesis; Internal fixation; Proximal femur

Mesh:

Substances:

Year:  2017        PMID: 29025610     DOI: 10.1016/S0020-1383(17)30658-7

Source DB:  PubMed          Journal:  Injury        ISSN: 0020-1383            Impact factor:   2.586


  6 in total

1.  CORR Insights®: Is an Acetabular Cage and Cement Fixation Sufficiently Durable for the Treatment of Destructive Acetabular Metastases?

Authors:  Benjamin K Potter
Journal:  Clin Orthop Relat Res       Date:  2019-06       Impact factor: 4.176

2.  Internal fixation versus endoprosthetic replacement of the proximal femur for metastatic bone disease: Single institutional outcomes.

Authors:  Charles A Gusho; Bishir Clayton; Nabil Mehta; Wassim Hmeidan; Matthew W Colman; Steven Gitelis; Alan T Blank
Journal:  J Orthop       Date:  2021-11-08

3.  Prosthesis or osteosynthesis for the treatment of a pathological hip fracture? A nationwide registry-based cohort study.

Authors:  Panagiotis Tsagkozis; Jessica Ehne; Rikard Wedin; Margareta Hedström
Journal:  J Bone Oncol       Date:  2021-06-14       Impact factor: 4.072

4.  Proximal femoral replacement for non-neoplastic conditions: a systematic review on current outcomes.

Authors:  Alberto Di Martino; Davide Pederiva; Barbara Bordini; Gabriele Di Carlo; Alessandro Panciera; Giuseppe Geraci; Niccolò Stefanini; Cesare Faldini
Journal:  J Orthop Traumatol       Date:  2022-03-29

5.  Preliminary results of a new intercalary modular endoprosthesis for the management of diaphyseal bone metastases.

Authors:  Kadir Büyükdoğan; Barlas Göker; Mazhar Tokgözoğlu; Ulukan İnan; Korhan Özkan; Tahsin Sami Çolak; Lercan Aslan; Mehmet Ali Deveci; Mehmet Ayvaz
Journal:  Jt Dis Relat Surg       Date:  2021-11-19

6.  Modified Unipolar Hemiarthroplasty for the Treatment of Metastatic Lesions of Proximal Femur with Pathological Fractures: Case Series of Six Patients.

Authors:  C Y Lim; S Mat-Hassan; M Awang; M F Md-Ariff; M A Hau-Abdullah
Journal:  Malays Orthop J       Date:  2019-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.